SVCM
MBX

Saturn V Capital Management’s MBX Biosciences MBX Stock Holding History

Saturn V Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,000
Closed -$332K – 25
2024
Q4 		$332K Buy
+18,000
New +$384K 0.13% 24

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Saturn V Capital Management's MBX Position: Q1 2025 in Review

Saturn V Capital Management sold out of MBX Biosciences (MBX) in Q1 2025, closing a stake of 18,000 shares — an estimated $332K sold.

Saturn V Capital Management first reported a position in MBX in Q4 2024 and held it in 1 quarter. The position peaked at $332K in Q4 2024. 79 funds tracked by Wall St. Rank hold MBX as of Q1 2025.

  • Saturn V Capital Management reported no remaining MBX Biosciences position as of Q1 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 18,000 MBX Biosciences shares in Q1 2025, an estimated $332K.
  • Saturn V Capital Management first reported a position in MBX Biosciences in Q4 2024 and held it in 1 quarter.
  • Saturn V Capital Management's MBX Biosciences position peaked at $332K in Q4 2024.
  • 79 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2025.

Based on Saturn V Capital Management's 13F filing for Q1 2025, filed 15 May 2025.